Physician profile
Haritha Pabbathi
NPI 1215000989
$18,611.69
in general payments reported to CMS, 2019-2025
53 companies · $2,448 in 2025
The $2,448 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,900 · 2020: $7,610 · 2021: $2,094 · 2022: $2,589 · 2023: $759 · 2024: $1,212 · 2025: $2,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,968 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,968.49 |
| Education | $450.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,967.15 | 2019-2025 | Lynparza, Enhertu |
| Pfizer International LLC | $3,100.00 | 2020 | |
| Pfizer INC. | $3,012.59 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,688.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $606.05 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $605.88 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $323.33 | 2019-2025 | |
| Taiho Oncology, INC. | $307.79 | 2019-2025 | |
| Amgen INC. | $286.90 | 2019-2020 | |
| Lilly USA, LLC | $271.25 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $256.19 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $253.47 | 2019-2020 | |
| Stemline Therapeutics INC. | $240.49 | 2023-2025 | Orserdu |
| Incyte Corporation | $216.56 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $213.20 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $199.49 | 2019-2025 | |
| Celgene Corporation | $168.70 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $152.10 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Glaxosmithkline, LLC. | $147.31 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Puma Biotechnology, INC. | $139.22 | 2019-2025 | |
| Exelixis INC. | $134.56 | 2019-2025 | Cabometyx |
| Abbvie INC. | $103.73 | 2025 | |
| Geron Corporation | $99.58 | 2025 | Rytelo |
| Genzyme Corporation | $95.62 | 2019-2025 | |
| Beigene USA, INC. | $82.68 | 2023-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $77.61 | 2019-2024 | Libtayo |
| Sobi, INC | $74.99 | 2024 | |
| Ucb, INC. | $72.65 | 2025 | Zilbrysq, Rystiggo |
| Beone Medicines USA, INC. | $68.08 | 2025 | Brukinsa |
| Kyowa Kirin, INC. | $58.93 | 2019-2020 | |
| Array Biopharma INC | $54.21 | 2024-2025 | Tukysa, Braftovi, Mektovi |
| Ipsen Biopharmaceuticals, INC | $44.63 | 2019-2020 | |
| Seagen INC. | $40.36 | 2019-2021 | |
| Legend Biotech USA INC. | $40.26 | 2025 | Carvykti |
| Astellas Pharma US INC | $39.09 | 2021-2025 | Vyloy |
| Deciphera Pharmaceuticals INC. | $38.16 | 2024-2025 | Qinlock, Romvimza |
| E.R. Squibb & Sons, L.L.C. | $27.58 | 2019-2020 | |
| Axsome Therapeutics, INC. | $26.66 | 2025 | Symbravo |
| Jazz Pharmaceuticals INC. | $25.56 | 2024 | |
| Myriad Genetic Laboratories, INC. | $24.75 | 2024 | Precisetumor |
| Azurity Pharmaceuticals, INC. | $22.42 | 2025 | Danziten |
| Immunogen, INC. | $22.04 | 2023 | Elahere |
| Sumitomo Pharma America, INC. | $20.97 | 2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $19.26 | 2024 | Ultomiris |
| G1 Therapeutics, INC. | $18.82 | 2023 | Cosela |
| Tempus Ai, INC | $18.63 | 2024 | |
| Servier Pharmaceuticals LLC | $17.74 | 2024 | |
| Nuvation Bio INC. | $17.46 | 2025 | Ibtrozi |
| Agios Pharmaceuticals, INC. | $15.46 | 2020 | |
| Novocure INC. | $14.37 | 2019 | |
| Mirati Therapeutics, INC. | $14.01 | 2024 | Krazati |
| Coherus Oncology, INC. | $12.18 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haritha Pabbathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.